JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subcloneGODFREY, Anna L; CHEN, Edwin; BIJOU, Fontanet et al.Blood. 2012, Vol 120, Num 13, pp 2704-2707, issn 0006-4971, 4 p.Article

Is the JAK2^V617F mutation detectable in healthy volunteers?MARTINAUD, Christophe; BRISOU, Patrick; MOZZICONACCI, Marie-Joelle et al.American journal of hematology. 2010, Vol 85, Num 4, pp 287-288, issn 0361-8609, 2 p.Article

New generation small-molecule inhibitors in myeloproliferative neoplasmsPASSAMONTI, Francesco; MAFFIOLI, Margherita; CARAMAZZA, Domenica et al.Current opinion in hematology. 2012, Vol 19, Num 2, pp 117-123, issn 1065-6251, 7 p.Article

Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?BAIN, Barbara J; AHMAD, Shahzaib.British journal of haematology. 2014, Vol 166, Num 6, pp 809-817, issn 0007-1048, 9 p.Article

JAK2 inhibitors: What's the true therapeutic potential?SANTOS, Fabio P. S; VERSTOVSEK, Srdan.Blood reviews. 2011, Vol 25, Num 2, pp 53-63, issn 0268-960X, 11 p.Article

Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria : PIH: Molecular mechanism, diagnosis, and treatment for myeloproliferative neoplasmsWADLEIGH, Martha; TEFFERI, Ayalew.International journal of hematology. 2010, Vol 91, Num 2, pp 174-179, issn 0925-5710, 6 p.Article

Intriguing outcome of JAK2V617F mutation seen in a patient with MYH9-related hereditary macrothrombocytopeniaFABRIS, Fabrizio; SCANDELLARI, Raffaella; VETTORE, Silvia et al.Thrombosis and haemostasis. 2010, Vol 104, Num 4, pp 858-859, issn 0340-6245, 2 p.Article

Myeloproliferative neoplasm induced by constitutive expression of JAK2^V617F in knock-in miceMARTY, Caroline; LACOUT, Catherine; MARTIN, Antoine et al.Blood. 2010, Vol 116, Num 5, pp 783-787, issn 0006-4971, 5 p.Article

Nuclear Janus-Activated Kinase 2/Nuclear Factor 1-C2 Suppresses Tumorigenesis and Epithelial-to-Mesenchymal Transition by Repressing Forkhead Box F1NILSSON, Jeanette; HELOU, Khalil; KOVACS, Anikó et al.Cancer research (Chicago, Ill.). 2010, Vol 70, Num 5, pp 2020-2029, issn 0008-5472, 10 p.Article

JAK2 V617F and ringed sideroblasts : not necessarily RARS-TSTEENSMA, David P; TEFFERI, Ayalew.Blood. 2008, Vol 111, Num 3, pp 1748-1748, issn 0006-4971, 1 p.Article

On the molecular origins of the chronic myeloproliferative disorders : it all makes senseKAUSHANSKY, Kenneth.Blood. 2005, Vol 105, Num 11, pp 4187-4190, issn 0006-4971, 4 p.Article

Transcriptional Profiling of Polycythemia Vera Identifies Gene Expression Patterns Both Dependent and Independent from the Action of JAK2V617FBERKOFSKY-FESSLER, Windy; BUZZAI, Monica; WEIJIA ZHANG et al.Clinical cancer research (Print). 2010, Vol 16, Num 17, pp 4339-4352, issn 1078-0432, 14 p.Article

JAK2^V617F : prevalence in a large Chinese hospital population. CommentaryPARDANANI, Animesh; XUESONG XU; QI ZHANG et al.Blood. 2007, Vol 109, Num 1, issn 0006-4971, 8,339-342 [5 p.]Article

Characterization of murine JAK2^V617F-positive myeloproliferative diseaseBUMM, Thomas G. P; ELSEA, Collin; CORBIN, Amie S et al.Cancer research (Baltimore). 2006, Vol 66, Num 23, pp 11156-11165, issn 0008-5472, 10 p.Article

Nouvelles anomalies moléculaires pronostiques : Myélofibrose = New prognostic molecular abnormalitiesMURATI, A.Correspondances en onco-hématologie. 2014, Vol 9, Num 1, pp 23-27, issn 1954-4820, 5 p.Article

Les formes familiales des syndromes myéloprolifératifs Philadelphie-négatifs: caractéristiques cliniques et moléculaires = Familial Philadelphia-negative myeloproliferative disorders: clinical and molecular characteristicsBELLANNECHANTELOT, Christine; SAINT-MARTIN, Cécile; MALAK, Sandra et al.Hématologie (Montrouge). 2011, Vol 17, Num 5, pp 331-341, issn 1264-7527, 11 p.Article

The complete evaluation of erythrocytosis: congenital and acquiredPATNAIK, M. M; TEFFERI, A.Leukemia. 2009, Vol 23, Num 5, pp 834-844, issn 0887-6924, 11 p.Article

The history of myeloproliferative disorders : before and after DameshekTEFFERI, A.Leukemia. 2008, Vol 22, issn 0887-6924, P3-P13, HSArticle

Essential thrombocythemia : scientific advances and current practiceTEFFERI, Ayalew.Current opinion in hematology. 2006, Vol 13, Num 2, pp 93-98, issn 1065-6251, 6 p.Article

Stratégies diagnostiques dans les syndromes myéloprolifératifs en 2008 : Syndrome myéloprolifératif hors LMC = Diagnosis of myeloproliferative disorders in 2008UGO, V.Correspondances en onco-hématologie. 2008, Vol 3, Num 3, pp 127-133, issn 1954-4820, 7 p.Article

The JAK2 V617F somatic mutation, mortality and cancer risk in the general populationNIELSEN, Camilla; BIRGENS, Henrik S; NORDESTGAARD, Børge G et al.Haematologica (Roma). 2011, Vol 96, Num 3, pp 450-453, issn 0390-6078, 4 p.Article

Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineageDA COSTA REIS MONTE-MOR, B; PLO, I; SAAD, S. T. O et al.Leukemia. 2009, Vol 23, Num 1, pp 144-152, issn 0887-6924, 9 p.Article

Mechanisms of Constitutive Activation of Janus Kinase 2-V617F Revealed at the Atomic Level Through Molecular Dynamics SimulationsLEE, Tai-Sung; WANLONG MA; XI ZHANG et al.Cancer. 2009, Vol 115, Num 8, pp 1692-1700, issn 0008-543X, 9 p.Article

CLINICAL IMPLICATIONS OF JAK2 MUTATIONS IN MYELOPROLIFERATIVE DISORDERSKNOOPS, L; HERMANS, C; FERRANT, A et al.Acta Clinica Belgica. 2008, Vol 63, Num 2, pp 93-98, issn 0001-5512, 6 p.Article

JAK2 V617F mutation is rare in idiopathic erythrocytosis : a difference from polycythemia veraYOSHINAGA, Kentaro; MORI, Naoki; WANG, Yan-Hua et al.International journal of hematology. 2008, Vol 88, Num 1, pp 82-87, issn 0925-5710, 6 p.Article